WellDoc, a Baltimore, MD-based digital health technology company, raised an additional $7.5m in an extension of the Series B funding round.
Johnson & Johnson Innovation, JJDC, Inc., participated in the recently announced Series B round, now totalling $29.5m. The investment is part of a broader collaboration between the company and LifeScan, Inc., a business within the Johnson & Johnson Diabetes Care Companies and provider of blood glucose monitoring solution for patients living with Type 2 diabetes.
Led by Kevin McRaith, CEO, WellDoc develops mobile solutions to drive behavioral and clinical change in chronic disease. The company has commercialized BlueStar, an FDA-cleared digital therapeutic for adults with type 2 diabetes, designed to fill the support gap between patients and providers during the time individuals live outside the healthcare system.
Under the collaboration, WellDoc’s BlueStar product will be integrated with LifeScan’s OneTouchVerio Flex Bluetooth Smart blood glucose monitoring system and OneTouch Reveal mobile app.
The collaboration will seek to leverage LifeScan’s blood glucose monitoring system and mobile application along with the data analytics and patient engagement of WellDoc’s clinically validated, reimbursable, mobile prescription therapy, BlueStar, to create a real-time, personalized approach for the
management of Type 2 diabetes.